VIVORYON
4,146
EUR
(-2.36%)
03/31/2025 - 15:35
Preclose 15 min delayed data - Euronext Amsterdam
| Open: | 4,185 |
| Change: | -100 |
| Volume: | 1,096,590 |
| Low: | 4,116 |
| High: | 4,200 |
| High / Low range: | 84 |
| Type: | Stocks |
| Ticker: | VVY |
| ISIN: | NL00150002Q7 |
VIVORYON news, videos and press releases
For more news please use our advanced search feature.
VIVORYON - More news...
VIVORYON - More news...
- 02/19/2025 - 17:00 Vivoryon Therapeutics N.V. Shares Highlights from Virtual R&D Update with KOL Speakers
- 02/11/2025 - 17:00 Vivoryon Therapeutics N.V. to Host Virtual R&D Update with KOL Speakers on February 18, 2025
- 01/14/2025 - 06:00 Vivoryon Therapeutics N.V. Provides R&D-Update Further Strengthening Development Pipeline in Kidney Disease
- 12/10/2024 - 06:00 Vivoryon Therapeutics N.V. Reports Q3 2024 Results and Highlights Progress on Varoglutamstat in Kidney Disease
- 12/09/2024 - 06:00 Vivoryon Therapeutics N.V. Presents Topline Phase 2 Data from VIVA-MIND Strongly Supporting Varoglutamstat’s Potential to Improve Kidney Function
- 12/04/2024 - 06:00 Vivoryon Therapeutics N.V. to Report Q3 2024 Financial Results and Operational Progress on December 10, 2024
- 10/26/2024 - 07:30 Vivoryon Therapeutics N.V. Presents Outstanding Phase 2b Results of Varoglutamstat on Kidney Function at ASN Kidney Week 2024
- 10/11/2024 - 13:20 Vivoryon Therapeutics N.V. Announces Late-breaking Oral Presentation at the American Society of Nephrology Kidney Week 2024
- 10/01/2024 - 05:00 Vivoryon Therapeutics N.V. Shares Highlights from Virtual Kidney Disease KOL Event
- 09/12/2024 - 05:00 Vivoryon Therapeutics N.V. Reports H1 2024 Progress Marked by Compelling Kidney Function Data and Execution of Strategy to Advance Varoglutamstat in Kidney Disease
- 09/05/2024 - 16:12 Vivoryon Therapeutics N.V. Announces Completion of Share Capital Reduction and Change to Articles of Association
- 09/05/2024 - 05:00 Vivoryon Therapeutics N.V. to Report Half Year 2024 Financial Results on September 12, and to Host KOL Event on September 30, 2024
- 07/18/2024 - 05:00 Vivoryon Therapeutics N.V. Announces New Data Showing Unique Treatment Effects of Varoglutamstat on Kidney Function in Patients with Diabetes and Outlines Proposed Clinical Development Plan in Diabetic Kidney Disease
- 07/09/2024 - 05:00 Vivoryon Therapeutics N.V. to Host R&D Update Call on July 18, 2024 Focused on Progress in Kidney Disease
- 06/21/2024 - 13:00 Vivoryon Therapeutics N.V. Reports Outcome of 2024 Annual General Meeting
- 05/23/2024 - 05:00 Vivoryon Therapeutics N.V. Reports Q1 2024 Financial Results and New Data Reinforcing Strategic Focus in Kidney Disease
- 05/15/2024 - 05:00 Vivoryon Therapeutics N.V. to Report Q1 2024 Financial Results and Operational Progress on May 23, 2024
- 05/08/2024 - 05:00 Vivoryon Therapeutics N.V. to Hold its 2024 Annual General Meeting on June 21, 2024
- 04/24/2024 - 05:00 Vivoryon Therapeutics N.V. Reports Full Year 2023 Financial Results and Provides Varoglutamstat and Strategic Updates
- 04/16/2024 - 05:00 Vivoryon Therapeutics N.V. to Report Full Year 2023 Financial Results and Operational Progress on April 24, 2024
- 03/15/2024 - 06:00 Vivoryon Therapeutics N.V. Announces Changes to Board Composition
- 03/04/2024 - 06:00 Vivoryon Therapeutics N.V. Provides Update on VIVIAD Phase 2b Study of Varoglutamstat in Early Alzheimer’s Disease
- 01/08/2024 - 06:00 Vivoryon Therapeutics N.V. to Host Investor Meetings in January 2024
- 12/06/2023 - 06:00 Vivoryon Therapeutics N.V. Reports Third Quarter 2023 Financial Results and Highlights Operational Progress
- 11/28/2023 - 06:00 Vivoryon Therapeutics N.V. to Report Q3 2023 Financial Results and Operational Progress on December 6, 2023
- 11/07/2023 - 06:00 Vivoryon Therapeutics N.V. to Present at Upcoming Investor Conference
- 10/26/2023 - 05:00 Vivoryon Therapeutics N.V. Provides Comprehensive Progress Report for Ongoing Varoglutamstat Clinical Program Following R&D Event and VIVA-MIND DSMB Dose Decision
- 10/23/2023 - 05:00 Vivoryon Therapeutics N.V. Reports Positive Outcome from Independent Data Safety Monitoring Board with Unanimous Decision for VIVA-MIND U.S. Study of Varoglutamstat in Alzheimer’s Disease to Proceed at Highest Investigated Dose
- 10/17/2023 - 13:32 Vivoryon Therapeutics N.V. Shares Highlights from Virtual R&D Event with Key Opinion Leaders
- 10/05/2023 - 05:00 Vivoryon Therapeutics N.V. Announces Virtual R&D Event with Key Opinion Leaders and Upcoming Conference Participation
